By Fineline Cube 
Eisai’s (TYO: 4523) China unit announced that the first batch of its innovative drug Urece (dotinurad) has officially arrived in Shanghai, signaling the drug’s imminent entry into the Chinese market. This marks a significant milestone for the treatment of gout with hyperuricemia in the region.
Drug Profile and Market Entry
Urece is the first selective urate transporter 1 (URAT1) inhibitor to be approved in China. It received regulatory approval in December last year and is expected to be available in major hospitals and e-commerce platforms by late July 2025.-Fineline Info & Tech